Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis

NCT02638038 is registered in ClinicalTrials.gov with InteKrin Therapeutics, Inc. as lead sponsor.

NCT NCT02638038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02638038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis
Lead sponsor
InteKrin Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
December 12, 2016
Enrollment
228 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing remitting